78 results
Is there an increase in markers of trombogenese (platelet activation, d-dimeer, von willebrandfactor, OPG) in elderly users of antipsychotics six to ten days after the start in comparison to the same markers before start of the antipsychotic…
To investigate the in vitro effect of pro- and anticoagulants on the hemostatic capacity of plasma from patients with liver cirrhosis.
Primary objective: to quantitatively characterize the pharmacokinetics and associated inter-individual and inter-occasion variability of prophylactic nadroparin in critically ill patients.Secondary objectives: To screen and possibly quantify the…
Primary :To evaluate the prothrombin time (PT) in healthy volunteers treated with edoxaban alone or preceded by apixaban.Secondary : To assess the effect of edoxaban alone or preceded by apixaban on additional pharmacodynamic (PD) assays: activated…
To assess the Pharmacokinetic and Pharmacodynamic properties of three dosages of Coagulation Factor VIIa (Recombinant) in congenital hemophilia A or B patientsTo assess the safety of three dosages of Coagulation factor VIIa (Recombinant) in…
-To assess the feasibility of relatively frequent measurements of whole blood platelet aggregometry using collagen as inducer;-To assess the effects of ASA treatment on collagen-induced platelet aggregation (primary endpoint);-To investigate the…
A study to investigate the safety, pharmacokinetics and pharmacodynamics of a new recombinant human factor VIIa in healthy males, compared to Novoseven.
We want to investigate if in critically ill patients use of LMWH is associated with stable plasma levels of anti-Xa activity. Furthermore, we want to investigate if GFR and circulation influence anti-Xa activity and which complications can occur.…
Study questionWhat is the effect of a single administration of prothrombin complex concentrate (CoFact) on the anticoagulant effect of a novel oral thrombin inhibitor (Dabigatran) and a novel oral factor Xa inhibitor (Rivaroxaban) in healthy human…
The primary objective is to evaluate the effect of a once-a-weekprophylaxis regimen with BAY 79-4980 on the protection from all bleeds compared to a three times-per-week prophylaxis regimen with rFVIII-FSWFI.
What is the effect of ex vivo incubation of plasma from patients with hemophilia A with or without inhibiting anti-factor VIII antibodies with recombinant human factor V mutants on activation of coagulation?
Primary objective: To evaluate the effect of intravenous vitamin K therapy on the vitamin K dependent coagulopathy in patients with peroxisomal biogenesis disorders measured with APTT, PT, FV, FVII, fibrinogen, d-dimer, thrombocytes and PIVKA.…
Primary outcome parameter is the amount of intra- and postoperative transfusions required. Secondary outcome parameters include intra- and postoperative blood loss, operation time, and postoperative complications and the outcome of…
- Assess the incidence of major bleeding and clinically relevant non-major bleeding- Assess the incidence of recurrent venous thromboembolism- Assess the asymptomatic deterioration in the thrombotic burden on repeat imaging- Characterize the…
The study has 3 objectives: 1. Proving that this form of RCA does not increase the risk of bleeding while achieving a degree of anticoagulation of the extracorporeal system that is similar to that when using LMWH. When this study shows that citrate…
The purpose of the study is to investigate the effect on the body of enoxaparin manufactured by the Sponsor (this is called pharmacodynamics) and to compare it with the pharmacodynamic effect of Clexane®. In addition, it will be investigated to what…
Primary objective:- To assess the safety of concizumab given as multiple s.c. doses to subjects with haemophilia ASecondary objectives:- To assess pharmacokinetics of concizumab in subjects with haemophilia A after multiple s.c. doses- To assess…
To evaluate the efficacy, safety and feasibility of combined immune modulation with rituximab, ITI and MSCs in terms of eradication of FVIII inhibitory activity in hemophilia A patients.
Primary objectiveTo evaluate and compare the single-dose pharmacokinetic of turoctocog alfa pegol from the pivotal process with turoctocog alfa pegol from the commercial process, each given as intravenous administrations of 50 U/kg to patients with…
To measure the effect of lowering or stopping biologicals on various coagulation parameters in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.